The role of glutathione in cancer

Cell Biochemistry and Function

Volumn 22, Issue 6, 2004, Pages 343-352

  Balendiran, Ganesaratnam K ^a   Dabur, Rajesh ^a   Fraser, Deborah ^a  

^a CITY OF HOPE NATIONAL MEDICAL CENTER   (United States)

Author keywords

Antioxidation; Cancer; Conjugation; Depletion; Detoxification; Glutathione; Polymorphism

Indexed keywords

ANTIOXIDANT; CISPLATIN; DISULFIDE; DOXORUBICIN; FREE RADICAL; GLUTATHIONE; GLUTATHIONE PEROXIDASE; GLUTATHIONE REDUCTASE; MELPHALAN; NICOTINAMIDE ADENINE DINUCLEOTIDE (PHOSPHATE) TRANSHYDROGENASE; THIOL DERIVATIVE; TRIPEPTIDE; VINCA ALKALOID;

ANIMAL CELL; ANIMAL TISSUE; ANTINEOPLASTIC ACTIVITY; CANCER; CARCINOGENESIS; CELL FUNCTION; CELL SURVIVAL; DETOXIFICATION; GENETIC POLYMORPHISM; GLUTATHIONE METABOLISM; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNE RESPONSE; IMMUNOMODULATION; NONHUMAN; OXIDATION REDUCTION REACTION; OXIDATIVE STRESS; PRIORITY JOURNAL; REVIEW; XENOBIOTIC METABOLISM;

ANTICARCINOGENIC AGENTS; DRUG RESISTANCE, NEOPLASM; GLUTATHIONE; HUMANS; NEOPLASMS;

EID: 8744226622     PISSN: 02636484     EISSN: None     Source Type: Journal    
DOI: 10.1002/cbf.1149     Document Type: Review

References (98)

1. Rahman I. Regulation of nuclear factor-kappa B, activator protein-1, and glutathione levels by tumor necrosis factor-alpha and dexamethasone in alveolar epithelial cells. Biochem Pharmacol 2000; 60: 1041-1049.
2. Tamba M, Quintiliani M. Kinetic studies of reactions involved in hydrogen transfer from glutathione to carbohydrate radicals. Radiat Phys Chem 1984; 23: 259-263.
3. Kosower NS, Kosower EM. The glutathione status of cells. Int Rev Cytol 1978; 54: 109-160.
4. Holmgren A. Thioredoxin and glutaredoxin systems. J Biol Chem 1989; 264: 13963-13966.
5. Schafer FQ, Buettner GR. Redox environment of the cell as viewed through the redox state of the glutathione disulfide/glutathione couple. Free Radic Biol Med 2001; 30: 1191-1212.
6. Modig H. Cellular mixed disulphides between thiols and proteins, and their possible implication for radiation protection. Biochem Pharmacol 1968; 17: 177-186.
7. Uotila L. Preparation and assay of glutathione thiol esters. Survey of human liver glutathione thiol esterases. Biochemistry 1973; 12: 3938-3943.
8. Ibarra C, Grillo MP, Lo Bello M, Nucettelli M, Bammler TK, Atkins WM. Exploration of in vitro pro-drug activation and futile cycling by glutathione S-transferases: thiol ester hydrolysis and inhibitor maturation. Arch Biochem Biophys 2003; 414: 303-311.
9. Salinas AE, Wong MG. Glutathione S-transferases-a review. Curr Med Chem 1999; 6: 279-309.
10. Eaton DL, Bammler TK. Concise review of the glutathione S-transferases and their significance to toxicology. Toxicol Sci 1999; 49: 156-164.
11. Griffith OW, Bridges RJ, Meister A. Evidence that the gamma-glutamyl cycle functions in vivo using intracellular glutathione: effects of amino acids and selective inhibition of enzymes. Proc Natl Acad Sci USA 1978; 75: 5405-5408.
12. Dickinson DA, Forman HJ. Cellular glutathione and thiols metabolism. Biochem Pharmacol 2002; 64: 1019-1026.
13. Deneke SM, Fanburg BL. Regulation of cellular glutathione. Am J Physiol 1989; 257: L163-L173.
14. Ristoff E, Larsson A. Patients with genetic defects in the gamma-glutamyl cycle. Chem Biol Interact 1998; 111-112: 113-121.
15. Schulman JD, Goodman SI, Mace JW, Patrick AD, Tietze F, Butler EJ. Glutathionuria: inborn error of metabolism due to tissue deficiency of gamma-glutamyl transpeptidase. Biochem Biophys Res Commun 1975; 65: 68-74.
16. Griffith OW, Meister A. Potent and specific inhibition of glutathione synthesis by buthionine sulfoximine (S-n-butyl homocysteine sulfoximine). J Biol Chem 1979; 254: 7558-7560.
17. Inoue M, Kinne R, Tran T, Arias IM. Glutathione transport across hepatocyte plasma membranes. Analysis using isolated rat-liver sinusoidal-membrane vesicles. Eur J Biochem 1984; 138: 491-495.
18. Anderson ME, Bridges RJ, Meister A. Direct evidence for inter-organ transport of glutathione and that the non-filtration renal mechanism for glutathione utilization involves gamma-glutamyl transpeptidase. Biochem Biophys Res Commun 1980; 96: 848-853.
19. Halliwell B. Free radicals, antioxidants, and human disease: curiosity, cause, or consequence? Lancet 1994; 344: 721-724.
20. Takebe G, Yarimizu J, Saito Y, et al. A comparative study on the hydroperoxide and thiol specificity of the glutathione peroxidase family and selenoprotein P. J Biol Chem 2002; 277: 41254-41258.
21. Toborek M, Hennig B. Fatty acid-mediated effects on the glutathione redox cycle in cultured endothelial cells. Am J Clin Nutr 1994; 59: 60-65.
22. Janssen YM, Van Houten B, Borm PJ, Mossman BT. Cell and tissue responses to oxidative damage. Lab Invest 1993; 69: 261-274.
23. Hayes JD, McLillen LI. Glutathione and glutathione dependent enzymes represent a co-ordinarily-regulated defense against oxidative stress. Free Rad Res 1999; 31: 273-300.
24. Fernandez PC, Machado J Jr, Heussler VT, Botteron C, Palmer GH, Dobbelaere DA. The inhibition of NF-kappaB activation pathways and the induction of apoptosis by dithiocarbamates in T cells are blocked by the glutathione precursor N-acetyl-L-cysteine. Biol Chem 1999; 380: 1383-1394.
25. Liang CM, Lee N, Cattell D, Liang SM. Glutathione regulates interleukin-2 activity on cytotoxic T-cells. J Biol Chem 1989; 264: 13519-13523.
26. Suthanthiran M, Anderson ME, Sharma VK, Meister A. Glutathione regulates activation-dependent DNA synthesis in highly purified normal human T lymphocytes stimulated via the CD2 and CD3 antigens. Proc Natl Acad Sci USA 1990; 87: 3343-3347.
27. Multhoff G, Meier T, Botzler C, et al. Differential effects of ifosfamide on the capacity of cytotoxic T lymphocytes and natural killer cells to lyse their target cells correlate with intracellular glutathione levels. Blood 1995; 85: 2124-2131.
28. Droge W, Schulze-Osthoff K, Mihm S, et al. Functions of glutathione and glutathione disulfide in immunology and immunopathology. FASEB J 1994; 8: 1131-1138.
29. Kaplowitz N, Aw TY, Ookhtens M. The regulation of hepatic glutathione. Annu Rev Pharmacol Toxicol 1985; 25: 715-744.
30. Ishikawa T. The ATP-dependent glutathione S-conjugate export pump. Trends Biochem Sci 1992; 17: 463-468.
31. Monks TJ, Anders MW, Dekant W, Stevens JL, Lau SS, van Bladeren PJ. Glutathione conjugate mediated toxicities. Toxicol Appl Pharmacol 1990; 106: 1-19.
32. Monks TJ, Lau SS. Toxicology of quinone-thioethers. Crit Rev Toxicol 1992; 22: 243-270.
33. Monks TJ, Lau SS. Glutathione conjugation as a mechanism for the transport of reactive metabolites. Adv Pharmacol 1994; 27: 183-210.
34. Carvalho M, Hawksworth G, Milhazes N, et al. Role of metabolites in MDMA (ecstasy)-induced nephrotoxicity: an in vitro study using rat and human renal proximal tubular cells. Arch Toxicol 2002; 76: 581-588.
35. Monks TJ, Ghersi-Egea JF, Philbert M, Cooper AJ, Lock EA. Symposium overview: the role of glutathione in neuroprotection and neurotoxicity. Toxicol Sci 1999; 51: 161-177.
36. Shaw CA, Bains JS. Synergistic versus antagonistic actions of glutamate and glutathione: the role of excitotoxicity and oxidative stress in neuronal disease. Cell Mol Biol (Noisy-le-grand) 2002; 48: 127-136.
37. Pompella A, Visvikis A, Paolicchi A, De Tata V, Casini AF. The changing faces of glutathione, a cellular protagonist. Biochem Pharmacol 2003; 66: 1499-1503.
38. Paolicchi A, Dominici S, Pieri L, Maellaro E, Pompella A. Glutathione catabolism as a signaling mechanism. Biochem Pharmacol 2002; 64: 1027-1035.
39. Midander J, Deschavanne PJ, Malaise EP, Revesz L. Survival curves of irradiated glutathione-deficient human fibroblasts: indication of a reduced enhancement of radiosensitivity by oxygen and misonidazole. Int J Radiat Oncol Biol Phys 1982; 8: 443-446.
40. Nguyen LN, Munshi A, Hobbs ML, Story MD, Meyn RD. Paclitaxel restores radiation-induced apoptosis in a bcl-2-expressing, radiation-resistant lymphoma cell line. Int J Radiat Oncol Biol Phys 2001; 49: 1127-1132.
41. Vukovic V, Nicklee T, Hedley DW. Microregional heterogeneity of non-protein thiols in cervical carcinomas assessed by combined use of HPLC and fluorescence image analysis. Clin Cancer Res 2000; 6: 1826-1832.
42. Vukovic V, Nicklee T, Hedley DW. Differential effects of buthionine sulphoximine in hypoxic and non-hypoxic regions of human cervical carcinoma xenografts. Radiother Oncol 2001; 60: 69-73.
43. Seidegard J, Vorachek WR, Pero RW, Pearson WR. Hereditary differences in the expression of the human glutathione transferase active on trans-stilbene oxide are due to a gene deletion. Proc Natl Acad Sci USA 1988; 85: 7293-7297.
44. Cartwright RA, Glashan RW, Rogers HJ, et al. Role of N-acetyltransferase phenotypes in bladder carcinogenesis: a pharmacogenetic epidemiological approach to bladder cancer. Lancet 1982; 2: 842-845.
45. Nakajima T, Elovaara E, Anttila S, et al. Expression and polymorphism of glutathione S-transferase in human lungs: risk factors in smoking-related lung cancer. Carcinogenesis 1995; 16: 707-711.
46. Inskip A, Elexperu-Camiruaga J, Buxton N, et al. Identification of polymorphism at the glutathione S-transferase, GSTM3 locus: evidence for linkage with GSTM1*A. Biochem J 1995; 312: 713-716.
47. Harris MJ, Coggan M, Langton L, Wilson SR, Board PG. Polymorphism of the Pi class glutathione S-transferase in normal populations and cancer patients. Pharmacogenetics 1998; 8: 27-31.
48. Ali-Osman F, Akande O, Antoun G, Mao JX, Buolamwini J. Molecular cloning, characterization, and expression in Escherichia coli of full-length cDNAs of three human glutathione S-transferase Pi gene variants. Evidence for differential catalytic activity of the encoded proteins. J Biol Chem 1997; 272: 10004-10012.
49. Hu X, Ji X, Srivastava SK, et al. Mechanism of differential catalytic efficiency of two polymorphic forms of human glutathione S-transferase P1-1 in the glutathione conjugation of carcinogenic diol epoxide of chrysene. Arch Biochem Biophys 1997; 345: 32-38.
50. Peters WH, Wormskamp NG, Thies E. Expression of glutathione S-transferases in normal gastric mucosa and in gastric tumors. Carcinogenesis 1990; 11: 1593-1596.
51. Strange RC, Spiteri MA, Ramachandran S, Fryer AA. Glutathione-S- transferase family of enzymes. Mutat Res 2001; 482: 21-26.
52. Guengerich FP, Thier R, Persmark M, Taylor JB, Pemble SE, Ketterer B. Conjugation of carcinogens by theta class glutathione S-transferases: mechanisms and relevance to variations in human risk. Pharmacogenetics 1995; 5(Spec. no.): S103-S107.
53. Landi S. Mammalian class theta GST and differential susceptibility to carcinogens: a review. Mutat Res 2000; 463: 247-283.
54. Park SK, Yoo KY, Lee SJ, et al. Alcohol consumption, glutathione S-transferase M1 and T1 genetic polymorphisms and breast cancer risk. Pharmacogenetics 2000; 10: 301-309.
55. Gudmundsdottir K, Tryggvadottir L, Eyfjord JE. GSTM1, GSTT1, and GSTP1 genotypes in relation to breast cancer risk and frequency of mutations in the p53 gene. Cancer Epidemiol Biomarkers Prev 2001; 10: 1169-1173.
56. Acevedo C, Opazo JL, Huidobro C, Cabezas J, Iturrieta J, Quinones Sepulveda L. Positive correlation between single or combined genotypes of CYP1A1 and GSTM1 in relation to prostate cancer in Chilean people. Prostate 2003; 57: 111-117.
57. Nakazato H, Suzuki K, Matsui H, et al. Association of genetic polymorphisms of glutathione-S-transferase genes (GSTM1, GSTT1 and GSTP1) with familial prostate cancer risk in a Japanese population. Anticancer Res 2003; 23(3C): 2897-2902.
58. Lee KM, Park SK, Kim SU, et al. N-acetyltransferase (NAT1, NAT2) and glutathione S-transferase (GSTM1, GSTT1) polymorphisms in breast cancer. Cancer Lett 2003; 196: 179-186.
59. Yuille M, Condie A, Hudson C, et al. Relationship between glutathione S-transferase M1, T1, and P1 polymorphisms and chronic lymphocytic leukemia. Blood 2002; 99: 4216-4218.
60. Suzuki T, Nishio K, Tanabe S. The MRP family and anticancer drug metabolism. Curr Drug Metab 2001; 2: 367-377.
61. Joncourt F, Oberli-Schrammli AE, Stadler M, et al. Patterns of drug resistance parameters in adult leukemia. Leuk Lymph 1995; 17: 101-109.
62. Perry RR, Mazetta JA, Levin M, Barranco SC. Glutathione levels and variability in breast tumors and normal tissue. Cancer 1993; 72: 783-787.
63. Redmond SM, Joncourt F, Buser K, et al. Assessment of P-glycoprotein, glutathione-based detoxifying enzymes and O6-alkylguanine-DNA alkyltransferase as potential indicators of constitutive drug resistance in human colorectal tumors. Cancer Res 1991; 51: 2092-2097.
64. Berger SJ, Gosky D, Zborowska E, Willson JK, Berger NA. Sensitive enzymatic cycling assay for glutathione: measurements of glutathione content and its modulation by buthionine sulfoximine in vivo and in vitro in human colon cancer. Cancer Res 1994; 54: 4077-4083.
65. Mulder TP, Manni JJ, Roelofs HM, Peters WH, Wiersma A. Glutathione S-transferases and glutathione in human head and neck cancer. Carcinogenesis 1995; 16: 619-624.
66. Cook JA, Pass HI, Iype SN, et al. Cellular glutathione and thiol measurements from surgically resected human lung tumor and normal lung tissue. Cancer Res 1991; 51: 4287-4294.
67. Oberli-Schrammli AE, Joncourt F, Stadler M, et al. Parallel assessment of glutathione-based detoxifying enzymes, O6-alkylguanine-DNA alkyltransferase and P-glycoprotein as indicators of drug resistance in tumor and normal lung of patients with lung cancer. Int J Cancer 1994; 59: 629-636.
68. Tatebe S, Unate H, Sinicrope FA, et al. Expression of heavy subunit of gamma-glutamylcysteine synthetase (gamma-GCSh) in human colorectal carcinoma. Int J Cancer 2002; 97: 21-27.
69. Soini Y, Napankangas U, Jarvinen K, Kaarteenaho-Wiik R, Paakko P, Kinnula VL. Expression of gamma-glutamyl cysteine synthetase in non-small cell lung carcinoma. Cancer 2001; 92: 2911-2919.
70. Seven A, Erbil Y, Seven R, et al. Breast cancer and benign breast disease patients evaluated in relation to oxidative stress. Cancer Biochem Biophys 1998; 16: 333-345.
71. Huang ZZ, Chen C, Zeng Z, et al. Mechanism and significance of increased glutathione level in human hepatocellular carcinoma and liver regeneration. FASEB J 2001; 15: 19-21.
72. Iida T, Mori E, Mori K, et al. Co-expression of gamma-glutamylcysteine synthetase sub-units in response to cisplatin and doxorubicin in human cancer cells. Int J Cancer 1999; 82: 405-411.
73. Ahmad S, Okine L, Le B, Najarian P, Vistica DT. Elevation of glutathione in phenylalanine mustard-resistant murine L1210 leukemia cells. J Biol Chem 1987; 262: 15048-15053.
74. Bailey HH, Gipp JJ, Ripple M, Wilding G, Mulcahy RT. Increase in gamma-glutamylcysteine synthetase activity and steady-state messenger RNA levels in melphalan-resistant DU-145 human prostate carcinoma cells expressing elevated glutathione levels. Cancer Res 1992; 52: 5115-5118.
75. Britten RA, Green JA, Warenius HM. Cellular glutathione (OSH) and glutathione S-transferase (GST) activity in human ovarian tumor biopsies following exposure to alkylating agents. Int J Radiat Oncol Biol Phys 1992; 24: 527-531.
76. Kalinina EV, Saprin AN, Solomka VS, Shcherbak NP, Chermnykh NS, Piruzian LA. Role of the antioxidant system and redox-dependent regulation of transcription factors bcl-2 and p53 in forming resistance of human K562 erythroleukemia cells to doxorubicin. Vopr Onkol 2001; 47: 595-600.
77. Kawai H, Kiura K, Tabata M, et al. Characterization of non-small-cell lung cancer cell lines established before and after chemotherapy. Lung Cancer 2002; 35: 305-314.
78. Draeger J, Peter G, Hohorst HJ. Deactivation of cyclophosphamide (NSC-26271) metabolites by sulfhydryl compounds. Cancer Treat Rep 1976; 60: 355-359.
79. Suzukake K, Vistica BP, Vistica DT. Dechlorination of L-phenylalanine mustard by sensitive and resistant tumor cells and its relationship to intracellular glutathione content. Biochem Pharmacol 1983; 32: 165-167.
80. Brandt EL, Griffin AC. Reduction of toxicity of nitrogen mustards by cysteine. Cancer 1951; 4: 1030-1035.
81. Frischer H, Ahmad T. Severe generalized glutathione reductase deficiency after antitumor chemotherapy with BCNU [1,3-bis(chloroethyl)-1-nitrosourea]. J Lab Clin Med 1977; 89: 1080-1091.
82. Shoemaker DD, Gormley PE, Cysyk RL. Biliary excretion of 4′-(9-acridinylamino)methanesulfon-m-anisidide (AMSA) in rats: effects of pretreatment with diethyl maleate, phenobarbital, and metyrapone. Drug Metab Dispos 1980; 8: 467-468.
83. Revis NW, Marusic N. Glutathione peroxidase activity and selenium concentration in the hearts of doxorubicin-treated rabbits. J Mol Cell Cardiol 1978; 10: 945-951.
84. Bachur NR, Gordon SL, Gee MV. A general mechanism for microsomal activation of quinone anticancer agents to free radicals. Cancer Res 1978; 38: 1745-1750.
85. Fujita E, Nagao Y. Tumor inhibitors having potential for interaction with mecepto enzymes and/or coenzymes. Bioorg Chem 1977; 6: 287-309.
86. De Bittencourt PI Jr, Curi R, Williams JF. Glutathione metabolism and glutathione S-conjugate export ATPase (MRP1/GS-X pump) activity in cancer. I. Differential expression in human cancer cell lines. Biochem Mol Biol Int 1998; 45: 1227-1241.
87. Zhang K, Chew M, Yang EB, Wong KP, Mack P. Modulation of cisplatin cytotoxicity and cisplatin-induced DNA cross-links in HepG2 cells by regulation of glutathione-related mechanisms. Mol Pharmacol 2001; 59: 837-843.
88. Exner R, Wessner B, Manhart N, Roth E. Therapeutic potential of glutathione. Wien Klin Wochenschr 2000; 112: 610-616.
89. Chen X, Batist O. Sensitization effect of L-2-oxothiazolidine-4- carboxylate on tumor cells to melphalan and the role of 5-oxo-L-prolinase in glutathione modulation in tumor cells. Biochem Pharmacol 1998; 56: 743-749.
90. Russo A, DeGraff W, Friedman N, Mitchell JB. Selective modulation of glutathione levels in human normal versus tumor cells and subsequent differential response to chemotherapy drugs. Cancer Res 1986; 46: 2845-2848.
91. Chen X, Carystinos GD, Batist G. Potential for selective modulation of glutathione in cancer chemotherapy. Chem Biol Interact 1998; 111-112: 263-275.
92. Sheehan D, Meade G. Chemical modulation of chemotherapy resistance in cultured oesophageal carcinoma cells. Biochem Soc Trans 2000; 28: 27-32.
93. Lewis AD, Duran GE, Lau DH, Sikic BI. Sensitization of drug resistant human ovarian cancer cells to cyanomorpholino doxorubicin (MRA-CN) by modulation of glutathione metabolism. Int J Radiat Oncol Biol Phys 1992; 22: 821-824.
94. Anderson CP, Keshelava N, Satake N, Meek WH, Reynolds CP. Synergism of buthionine sulfoximine and melphalan against neuroblastoma cell lines derived after disease progression. Med Pediatr Oncol 2000; 35: 659-062.
95. Pan B, Yao KS, Monia BP, et al. Reversal of cisplatin resistance in human ovarian cancer cell lines by a c-jun antisense oligodeoxynucleotide (ISIS 10582): evidence for the role of transcription factor overexpression in determining resistant phenotype. Biochem Pharmacol 2002; 63: 1699-1707.
96. Kondo T, Lida T. Gamma-GCS and glutathione- new molecular targets in cancer treatment. Gan To Kagaku Ryoho 1997; 24: 2219-2225.
97. Orrenius S, Jones DP. Functions of glutathione in drug metabolism. In Functions of Glutathione in Liver and Kidney, Sies H, Wendel A (eds). Springer-Verlag: Berlin, 1978; 164-175.
98. Bailey HH, Ripple G, Tutsch KD, et al. Phase I study of continuous-infusion L-S,R-buthionine sulfoximine with intravenous melphalan. J Natl Cancer Inst 1997; 89: 1789-1796.